MX2016008725A - Formulacion compuesta para administracion oral que comprende ezetimibe y rosuvastatina. - Google Patents
Formulacion compuesta para administracion oral que comprende ezetimibe y rosuvastatina.Info
- Publication number
- MX2016008725A MX2016008725A MX2016008725A MX2016008725A MX2016008725A MX 2016008725 A MX2016008725 A MX 2016008725A MX 2016008725 A MX2016008725 A MX 2016008725A MX 2016008725 A MX2016008725 A MX 2016008725A MX 2016008725 A MX2016008725 A MX 2016008725A
- Authority
- MX
- Mexico
- Prior art keywords
- ezetimibe
- rosuvastatin
- composite formulation
- oral administration
- particle size
- Prior art date
Links
- 239000002131 composite material Substances 0.000 title abstract 4
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 title abstract 4
- 229960000815 ezetimibe Drugs 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 title abstract 3
- 229960000672 rosuvastatin Drugs 0.000 title abstract 3
- 239000002245 particle Substances 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 239000000479 mixture part Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se proporciona una formulación compuesta sólida para administración oral, incluyendo la formulación compuesta sólida: una parte de gránulos de ezetimibe, que incluye ezetimibe, teniendo dicho ezetimibe una distribución de tamaños de partículas en la que el tamaño medio de partículas d(0.9) para el 90% inferior es alrededor de 10 µm o menos; y una parte de mezcla de rosuvastatina, que incluye rosuvastatina o una sal farmacéuticamente aceptable de la misma, y un método para preparar la formulación compuesta.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130167156 | 2013-12-30 | ||
| KR1020140071081A KR20150079373A (ko) | 2013-12-30 | 2014-06-11 | 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 |
| PCT/KR2014/013087 WO2015102400A1 (en) | 2013-12-30 | 2014-12-30 | Composite formulation for oral administration comprising ezetimibe and rosuvastatin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016008725A true MX2016008725A (es) | 2017-02-28 |
Family
ID=53791740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016008725A MX2016008725A (es) | 2013-12-30 | 2014-12-30 | Formulacion compuesta para administracion oral que comprende ezetimibe y rosuvastatina. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US10434067B2 (es) |
| EP (1) | EP3089739A4 (es) |
| JP (1) | JP2017500303A (es) |
| KR (2) | KR20150079373A (es) |
| CN (1) | CN105873571B (es) |
| AR (1) | AR098996A1 (es) |
| AU (1) | AU2014374552B2 (es) |
| CA (1) | CA2933178A1 (es) |
| CL (1) | CL2016001654A1 (es) |
| CR (1) | CR20160293A (es) |
| DO (1) | DOP2016000159A (es) |
| GT (1) | GT201600137A (es) |
| MX (1) | MX2016008725A (es) |
| MY (1) | MY187637A (es) |
| NI (1) | NI201600093A (es) |
| PE (1) | PE20161072A1 (es) |
| PH (1) | PH12016501196B1 (es) |
| RU (1) | RU2683937C2 (es) |
| SG (1) | SG10201805657PA (es) |
| SV (1) | SV2016005236A (es) |
| TW (1) | TWI655944B (es) |
| UA (1) | UA117685C2 (es) |
| UY (1) | UY35932A (es) |
| WO (1) | WO2015102400A1 (es) |
| ZA (1) | ZA201603934B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX390899B (es) | 2015-10-30 | 2025-03-21 | Cancer Prevention Pharmaceuticals Inc | Formulación de combinación de dosis fija, eflornitina y sulindaco. |
| EP3243506A1 (en) | 2016-05-09 | 2017-11-15 | Adamed sp. z o.o. | Pharmaceutical composition |
| JP2017210455A (ja) * | 2016-05-27 | 2017-11-30 | ニプロ株式会社 | エゼチミブ含有医薬組成物 |
| CZ2016538A3 (cs) | 2016-09-05 | 2018-03-14 | Zentiva, K.S. | Farmaceutická kompozice obsahující dvě rozdílné účinné látky |
| CZ2016539A3 (cs) * | 2016-09-05 | 2018-03-14 | Zentiva, K.S. | Farmaceutická kompozice obsahující dvě rozdílné účinné látky a způsob její přípravy |
| KR101910902B1 (ko) * | 2016-11-03 | 2018-10-24 | 한미약품 주식회사 | 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합제제 |
| KR102206535B1 (ko) * | 2016-11-29 | 2021-01-22 | 한미약품 주식회사 | 에제티미브 및 로수바스타틴을 포함하는 경구용 복합정제 |
| JP6848469B2 (ja) * | 2017-01-20 | 2021-03-24 | ニプロ株式会社 | エゼチミブ含有医薬組成物の製造方法 |
| JP7115825B2 (ja) * | 2017-06-28 | 2022-08-09 | 日医工株式会社 | エゼチミブ含有経口製剤及びその製造方法 |
| JP2019014700A (ja) * | 2017-07-11 | 2019-01-31 | 大原薬品工業株式会社 | エゼチミブ含有口腔内崩壊錠及びその製造方法 |
| JP6937195B2 (ja) * | 2017-09-01 | 2021-09-22 | 興和株式会社 | 医薬組成物 |
| KR102569271B1 (ko) * | 2018-03-19 | 2023-08-23 | 한미약품 주식회사 | 에제티미브 및 로수바스타틴을 포함하는 약제학적 복합제제 |
| GR1009727B (el) * | 2018-11-28 | 2020-04-14 | Elpen Αε Φαρμακευτικη Βιομηχανια | Μονολιθικη σταθερη φαρμακοτεχνικη μορφη ταχειας αποδεσμευσης εζετιμιμπης και ροσουβαστατινης |
| WO2021019499A1 (en) | 2019-07-31 | 2021-02-04 | TECNIMEDE - Sociedade Técnico-medicinal, SA | Solid oral multiple-unit immediate release compositions, methods and uses thereof |
| TWI878600B (zh) * | 2020-08-25 | 2025-04-01 | 南韓商大熊製藥股份有限公司 | 用於治療或預防高血壓及高膽固醇血症之單一劑型的醫藥組成物 |
| CN112999178A (zh) * | 2021-03-01 | 2021-06-22 | 乐普制药科技有限公司 | 一种依折麦布匹伐他汀钙复方双层片剂 |
| GB2622822A (en) * | 2022-09-28 | 2024-04-03 | Novumgen Ltd | A rapidly disintegrating tablet of rosuvastatin and its process of preparation |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| EP0634175B1 (de) | 1993-07-15 | 2001-01-10 | F. Hoffmann-La Roche Ag | Pharmazeutische Kombination, die einen Hemmer des Renin-Angiotensin-Systems und einen Endothelin-Antagonisten enthält |
| US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| EP1347987B1 (en) | 2000-12-20 | 2004-10-13 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
| SK288217B6 (sk) | 2001-01-26 | 2014-08-05 | Merck Sharp & Dohme Corp. | Zmes, terapeutická kombinácia, farmaceutický prostriedok a ich použitie |
| HUP0401318A3 (en) | 2001-08-22 | 2008-03-28 | Sanofi Aventis Deutschland | Combined preparations containing 2,3,4,5-tetrahydro-benzo[b]thiepine-1,1-dioxide derivatives and other active substances, and the use thereof |
| WO2005011586A2 (en) * | 2003-07-28 | 2005-02-10 | Dr. Reddy's Laboratories, Inc. | Treatment and preventi0n of cardiovascular events |
| EP1865947A1 (en) | 2005-04-04 | 2007-12-19 | Pontificia Universidad Catolica de Chile | The use of ezetimibe in the prevention and treatment of cholesterol gallstones |
| US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| US20070275052A1 (en) | 2006-05-24 | 2007-11-29 | Glenmark Pharmaceuticals Limited | Pharmaceutical compositions containing sterol inhibitors |
| EP2125715A2 (en) | 2007-01-24 | 2009-12-02 | Krka | Process for the preparation of ezetimibe and derivatives thereof |
| EP2120882A2 (en) | 2007-02-23 | 2009-11-25 | Krka | Pharmaceutical composition containing a cholesterol absorption inhibitor |
| EP2182925A2 (en) | 2007-07-27 | 2010-05-12 | Cipla Limited | Pharmaceutical compositions and process for making them |
| WO2009024889A2 (en) * | 2007-08-21 | 2009-02-26 | Ranbaxy Laboratories Limited | Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe |
| JP5566288B2 (ja) | 2008-05-30 | 2014-08-06 | 武田薬品工業株式会社 | 複素環化合物 |
| JP2011525901A (ja) | 2008-06-27 | 2011-09-29 | アブディ イブラヒム イラク サナイ ベ ティカレット アノニム シルケティ | ロスバスタチンカルシウム含有医薬組成物 |
| ATE536172T1 (de) * | 2009-03-13 | 2011-12-15 | Sanovel Ilac Sanayi Ve Ticaret As | Ezetimibzusammensetzungen |
| US20110196383A1 (en) | 2009-05-05 | 2011-08-11 | Atherolysis Medical, Inc | Atherosclerotic Plaque Dissolution Composition |
| EP2448919A2 (en) | 2009-07-02 | 2012-05-09 | Mahmut Bilgic | Solubility and stability enchancing pharmaceutical formulation |
| TR201009397A2 (tr) | 2010-11-11 | 2012-05-21 | Bi̇lgi̇ç Mahmut | Rosuvastatin içeren farmasötik bileşimler. |
| EP2566465A2 (en) * | 2010-05-04 | 2013-03-13 | Mahmut Bilgic | Stable rosuvastatin formulations |
| KR101248804B1 (ko) * | 2010-05-14 | 2013-03-29 | 한미사이언스 주식회사 | ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제 |
| EP2468258A1 (en) | 2010-12-22 | 2012-06-27 | LEK Pharmaceuticals d.d. | Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient |
| WO2013066279A1 (en) * | 2011-10-13 | 2013-05-10 | Mahmut Bilgic | Solid dosage forms comprising ezetimibe |
| US9763885B2 (en) | 2012-05-01 | 2017-09-19 | Althera Laboratories Ltd. | Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases |
| KR101335365B1 (ko) * | 2012-05-22 | 2013-12-02 | 건일제약 주식회사 | 오메가-3 지방산 또는 그의 알킬 에스테르 및 스타틴계 약물을 함유하는 다층코팅 형태의 경구투여용 약학 조성물 |
| MX2012014970A (es) * | 2012-12-18 | 2013-08-27 | Hetlabs Mexico S A De C V | Composiciones farmaceuticas que comprenden ezetimiba y rosuvastatina de calcio amorfo novedoso. |
| KR102240429B1 (ko) * | 2013-05-06 | 2021-04-15 | 한미약품 주식회사 | 로수바스타틴 또는 이의 약학적으로 허용되는 염이 함유된 필름 코팅층을 포함하는 복합 제형 |
-
2014
- 2014-06-11 KR KR1020140071081A patent/KR20150079373A/ko active Pending
- 2014-12-29 TW TW103146067A patent/TWI655944B/zh not_active IP Right Cessation
- 2014-12-29 KR KR1020140192374A patent/KR20150079454A/ko not_active Ceased
- 2014-12-29 UY UY0001035932A patent/UY35932A/es not_active Application Discontinuation
- 2014-12-30 MY MYPI2016000980A patent/MY187637A/en unknown
- 2014-12-30 EP EP14876988.8A patent/EP3089739A4/en not_active Withdrawn
- 2014-12-30 MX MX2016008725A patent/MX2016008725A/es unknown
- 2014-12-30 WO PCT/KR2014/013087 patent/WO2015102400A1/en not_active Ceased
- 2014-12-30 SG SG10201805657PA patent/SG10201805657PA/en unknown
- 2014-12-30 PE PE2016000976A patent/PE20161072A1/es unknown
- 2014-12-30 US US15/108,940 patent/US10434067B2/en not_active Expired - Fee Related
- 2014-12-30 UA UAA201605792A patent/UA117685C2/uk unknown
- 2014-12-30 JP JP2016537529A patent/JP2017500303A/ja active Pending
- 2014-12-30 AU AU2014374552A patent/AU2014374552B2/en not_active Expired - Fee Related
- 2014-12-30 CA CA2933178A patent/CA2933178A1/en not_active Abandoned
- 2014-12-30 CN CN201480071651.8A patent/CN105873571B/zh active Active
- 2014-12-30 AR ARP140104955A patent/AR098996A1/es unknown
- 2014-12-30 CR CR20160293A patent/CR20160293A/es unknown
- 2014-12-30 RU RU2016123828A patent/RU2683937C2/ru active
-
2016
- 2016-06-09 ZA ZA2016/03934A patent/ZA201603934B/en unknown
- 2016-06-17 PH PH12016501196A patent/PH12016501196B1/en unknown
- 2016-06-24 DO DO2016000159A patent/DOP2016000159A/es unknown
- 2016-06-28 SV SV2016005236A patent/SV2016005236A/es unknown
- 2016-06-28 GT GT201600137A patent/GT201600137A/es unknown
- 2016-06-28 NI NI201600093A patent/NI201600093A/es unknown
- 2016-06-28 CL CL2016001654A patent/CL2016001654A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016008725A (es) | Formulacion compuesta para administracion oral que comprende ezetimibe y rosuvastatina. | |
| SG10201810985XA (en) | Tofacitinib oral sustained release dosage forms | |
| EA033689B9 (ru) | Ингибиторы g12c kras | |
| MX2015012414A (es) | Sal de omecamtiv mecarbilo y proceso para preparar la sal. | |
| SG10201804817TA (en) | Delayed release compositions of linaclotide | |
| SG10201811586YA (en) | Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof | |
| MX2015012743A (es) | Compuesto de pirazol-amida y sus usos farmaceuticos. | |
| MX368903B (es) | Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas. | |
| PH12017502376A1 (en) | Oral solid formulation containing irinotecan and method of preparing the same | |
| WO2014114255A3 (zh) | 一种定位速释生物粘附剂及应用 | |
| MY186698A (en) | Solid forms of ceftolozane | |
| HUE040666T2 (hu) | Ibandronsavat vagy gyógyászatilag elfogadható sóját és D vitamint tartalmazó, orális beadásra alkalmas szilárd kompozíció | |
| WO2017103600A8 (en) | Preparation of respirable zafirlukast particles | |
| MX2015000179A (es) | Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas. | |
| EP3648745A4 (en) | PHARMACEUTICAL COMPOSITION WITH SPHERICAL TABLET OF MULTIPLE UNITS WITH AMEOMEPRAZOLE AND SPHERICAL PHARMACEUTICAL SALT THEREOF AND METHOD FOR MANUFACTURING THE PHARMACEUTICAL COMPOSITION | |
| IN2013MU01177A (es) | ||
| MX2015009891A (es) | Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion. | |
| PH12016502540B1 (en) | Pharmaceutical dosage forms | |
| MY197281A (en) | Oral composite tablet comprising ezetimibe and rosuvastatin | |
| WO2016187595A3 (en) | Oral pharmaceutical composition of methylergonovine | |
| NZ728386A (en) | Use of phthalide compound | |
| UA80535U (uk) | Фармацевтична композиція для лікування сексуальної дисфункції |